Amphastar Pharmaceuticals (AMPH) Jefferies Global Healthcare Conference 2026 summary

Company Overview and Strategic Direction

• Focus on complex generics, hospital injectables, and expansion into proprietary and biosimilar products, with several in development.

• Operates a fully integrated, one-stop business model with in-house R&D, manufacturing, and distribution, ensuring quality and compliance.

• Technical expertise in peptides and clinical trials leveraged for proprietary pipeline advancement.

• Recent in-licensing of oncology and ophthalmology assets from China, emphasizing peptide-based products.

• Business development now prioritizes later-stage, de-risked proprietary assets closer to market.

Strategic Vision and Business Model

• Focuses on high quality, efficiency, and technology, resulting in strong net income margins and consistent revenue growth from 2018 to 2025.

• Strategic R&D investment of $369M over five years supports a diverse and scalable proprietary pipeline.

• Capital allocation prioritizes R&D, CapEx, share buybacks, and opportunistic business development.

Revenue Drivers and Financial Outlook

• Mid to high single-digit revenue growth expected, driven primarily by the generic Atrovent (ipratropium bromide) launch with six months exclusivity.

• Annual revenue grew from $499M in 2021 to $732M in 2024, with adjusted EPS rising at a 24% CAGR.

• Primatene Mist and API sales from China also contribute to growth.

• BAQSIMI guidance lowered to flat to up single digits, with growth expected in the final three quarters of the year.

• EBITDA margin expected to recover after Q1 trough, with gross margin improvement and G&A normalization post-2024.